2026年10月16日星期五
M
寰宇通鑑
全球快訊
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes

來源 柳叶刀 Lancet剛剛
內容摘要

This item is a 英文-language original; headline and summary shown as published.

Karl Deisseroth, Peter Hegemann, and Georg Nagel have been awarded the 2026 Nobel Prize in Physiology or Medicine. Talha Burki reports.

本站僅提供標題與摘要索引，完整內容與版權均歸原發布方所有，請點擊原文連結閱讀。

前往原文
所屬頻道
健康
所屬地區
英國
原文語種
English
條目編號
health-68ca0983

Comments 0 comments

No comments yet. Be the first.

[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes · 寰宇通鑑